H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Savara Inc (SVRA) today and set a price target of $22. The company’s shares closed yesterday at $10.72.
Fein said:
“Valuation and risks to achievement of target price. Our price target of $22/share is based on an equally weighted composite of: (a) $24/share, as a 30x multiple of taxed and diluted $4.72 discounted back to FY19 at 25% (in line with the expected PE multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $20/share (discounted cash flow analysis using a 14% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 3.7% and a 41.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Savara Inc has an analyst consensus of Strong Buy, with a price target consensus of $21.67, which is a 102.1% upside from current levels. In a report issued on May 6, Ladenburg also maintained a Buy rating on the stock with a $21 price target.
See today’s analyst top recommended stocks >>
Based on Savara Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.51 million. In comparison, last year the company had a GAAP net loss of $26.85 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
